Career & Tools
In this talk, Dr. Zesbo will share several case studies of product candidates (biologics) as they evolved within the industry along with important lessons learned regarding transitioning from academia to industry.
The first talk in the Center for Science and Engineering Partnerships' Fall âQuarter series âis a career talk from a biopharmaceutical veteran with numerous successful ventures in the Biotechnology industry.
In this talk, âDr. Krisztina Zsebo will share several case studies of product candidates (biologics) as they evolved within the industry along with important lessons learned regarding transitioning from academia to industry.
Career Talk: From the Bench to the Board Room, A Career in Biotechnology
Krisztina M. Zsebo, Ph.D., President, Biovest Consulting, LLC
Thursday, Oct. 6, 2-3 p.m.
Elings 1601
Light refreshments âprovided
RSVP at: https://csep.cnsi.ucsb.edu/forms/PDS/Registration.php
Abstract
Dr. Zsebo is a biopharmaceutical veteran with 32 years of experience and numerous successful ventures in the Biotechnology industry.
ââShe began her career with eight years at Amgen in research and product development where she worked on the discovery of NEUPOGEN®, Stem Cell Factor, and various aspects of EPOGEN® development. ââDr. Zsebo holds a B.S. in Biochemistry (University of Maryland), an M.S. in Biochemistry and Biophysics (Oregon State University), and a Ph.D. in Comparative Biochemistry and Molecular Biology (UC Berkeley). She has published over 100 articles on biotechnology and holds 21 patents in the biotech field.
Most recently, she was CEO & President of Celladon Corporation, where she took the company public and led a team of researchers who took a basic research project through to Phase 2b clinical trials. She has been an Entrepreneur in Residence at Enterprise Partners Venture Capital, CEO & President of Remedyne Corporation, and Executive VP of Connetics Corporation. When heading up the Biopharmaceutical and Implant Division of ALZA Corporation, she oversaw the development and filing of the NDA for Viadur®, an implantable drug/device for prostate cancer patients. And when she was Executive VP of Research and Product Development at Cell Genesys, she filed their first IND for a gene therapy product for AIDS and managed the division that spun off to become Abgenix, one of the most successful biotech companies.
Sponsored by: Center for Bioengineering, Graduate Students for Diversity in Science, Women in Science and Engineering, and PDS.